Voydeya: A Real Life Example of EMA Policy 0070 in Rare Disease

04 December 2024

Raquel Billiones, PhD and Alison McIntosh, PhD

for the CORE Reference Team




Clinical Trial Data: Transparency and Disclosure

Presenter: Dr Alison Mcintosh



EUROPEAN MEDICAL WRITERS ASSOCIATION


Clinical Trial & Data Transparency Timeline



EUROPEAN MEDICAL WRITERS ASSOCIATION

Billiones. The clinical research transparency journey. Medical Writing Volume 33 (3), 6-7; September 2024

Why Disclose?






Source: From EMA website; reused and adapted with permission



EMA Policy 0070 Timeline


EUROPEAN MEDICAL WRITERS ASSOCIATION





EMA Policy 0070 Relaunch

Clinical data publication timeline (iMAA and line extension applications)



5 Clinical Data Publication procedural timelines

https://www.ema.europa.eu/en/documents/presentation/presentation-cdp-procedural-timelines_en.pdf






EUROPEAN MEDICINES AGENCY

EMA Clinical Data Website (since 20 October 2016)

EMA website: <u>https://clinicaldata.ema.europa.eu</u>

Account needed





Policy 0070: Brief Introduction to Anonymisation Report (AnR)

Presenter: Dr Alison Mcintosh



EUROPEAN MEDICAL WRITERS ASSOCIATION

Anonymisation Report (AnR) Template

• New for Policy 0070 Relaunch

AnR Form Template (released 24 May 2024) AnR Form Instructions (released 24 May 2024)

Both can be downloaded from <u>https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/clinical-data-publication/support-industry-clinical-data-publication</u>



CORE Reference Webinar 07 June 2024

- Included general introduction to Policy 0070 Anonymisation Report (AnR) Template
 - See <u>https://www.core-reference.org/news-summaries/core-reference-seminar-emwa-valencia-may-2024-and-webinar-07-june-2024/</u>
 - See <u>https://www.core-reference.org/media/1088/core-reference-seminar-emwa-valencia-may-2024-and-webinar-07-june-2024-slides.pdf</u>
 - Refer to webinar slides 21 37 or presentation video at 30 58 minutes



Brief Recap

- AnR template used for all clinical data publication submissions (EMA/Health Canada or both)
- AnR describes
 - Anonymisation strategy adopted for each individual document package
 - Data protection consideration taken into account when deciding on the anonymisation strategy
- Structured Data Fields
 - Limited free text sections
- Clinical Data Publication (CDP) Questions and Answers (Q&As) updated and released 26 Jul 2023 (Rev 3): Section 3 covers info regarding anonymisation reports
 - <u>https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-qas-external-guidance-policy-0070-clinical-data-publication-cdp_en.pdf</u>



AnR Template Structure

Heading Structure

	Section	Heading
	(A)	Application information
	1 (B,C)	Anonymisation Methodology
	2	Identification of Data variables
	2.1 (D)	Direct Identifiers
	2.2 (E)	Indirect Identifiers
<	3 (F-M)	Risk Assessment
	4 (N-Q)	Data Utility
	5 (R)	Deviations
	6	Attestations

ß	Please fill out the following form. You cannot save data typed into this form.
	Please print your completed form if you would like a copy for your records.

Anonymisation Report

Version 1.1

*Please consult the instructions before filling out this form.		
Application Information		
Date Prepared		
► Product Name		
Active Ingredient/INN		
EMA Procedure Number		
Applicant/MAH		
Health Canada Control Number		
A) Are there any indirect identifiers present within the clinical information package?		
○ Yes		
No		
1. Anonymisation Methodology		
B) What anonymisation method was used to measure risk?		
C Qualitative		
C Quantitative		
C Both		
C) Please select the overlay text employed for redaction.		
C PI (Personal Information)		
PPD (Personal Protected Data)		

Information in this section provides greater context for the chosen anonymisation strategy



EUROPEAN MEDICAL WRITERS ASSOCIATION

F) Please input the selected reference population.

Study participants enrolled in each individual CTs in this submission

Study participants enrolled in each individual CTs in this submission

Pooled study participants enrolled across all CTs in this submission Pooled healthy study participants and pooled patients in this submission

Study participants enrolled in CTs for same indication, led around the same time/locations with same investigational product/sponsor Study participants enrolled in CTs for same indication, led around the same time/locations, with any sponsor Study participants for all known studies within the same indication

Other

3. Risk Assessment

F) Please input the selected reference population.

Select 'Yes' or 'No' if the product is intended to treat rare disease populations/conditions.

If yes then must describe the characteristics of the population(s) in the free text box that appears

Special population: e.g.,

pediatric, geriatric, pregnant or breastfeeding women. In the context of anonymisation, special populations might warrant special attention as they often represent a specific subset of participants as well as not necessarily sharing all key characteristics of the general reference population

	G) to this product indicated in the treatment of a rare disease/condition?				
	Yes				
	H) Were special populations involved in the tria	als?			
	€Yes				
	○ No				
	Please describe the characteristics of the special population(s) below.				
	I) Please input initial risk of reidentification.				
	J) Please input target risk threshold.				
	K) Please input residual risk.				
	L) Did some of the above indirect identifiers require consideration due to the sensitivity of the information?				
	○ Yes				
	O No				

The selection of the appropriate reference population determines the total patient group size and the level of anonymisation that is necessary to reduce the risk of patient reidentification. (Pull down menu selection)

Rare disease: a life-threatening, seriously debilitating or serious and chronic condition affecting a small number of patients. The definitions of a rare disease in Canada and the EU both indicate a prevalence of fewer than 5 in 10,000 persons.

Input the initial risk of reidentification approximated. In general, a qualitative value such as high, moderate, low can be included, as applicable. For quantitative approaches, maximum risk observed prior to anonymisation should be provided, as applicable.



3. Risk Assessment Guidance

• Template Instructions:

"Section M: In the space below, provide a clear and concise explanation for why the selected methodology (qualitative or quantitative) was used. Please also provide an explanation regarding the limitations of the approach"

Instruction sheet further guidance:

"Provide greater context on chosen anonymisation techniques (i.e redaction, transformation, recoding etc.) with reference to the different sections of the clinical documents (i.e. demographic tables, summaries, narratives etc.) and why that specific approach was deemed the most suitable with respect to the risk assessment conducted as well as the technical means available"



Real-life Example EMA Policy 0070: Voydeya

Presenter:

Raquel Billiones, PhD

Alexion (AstraZeneca Rare Disease Unit)



EVAN EUROPEAN MEDICAL WRITERS ASSOCIATION

Voydeya information presented here are available in the public domain under

Home - Clinical Data Publication - clinicaldata.ema.europa.eu



Views and opinions are those of the presenter and do not necessarily reflect those of EMWA or Alexion



Real-life Example EMA Policy 0070: Voydeya

- Danicopan, a small molecule, oral
- Initial MAA
- New chemical entity
- Orphan drug designation

Search - Clinical Data Publication - clinicaldata.ema.europa.eu


	Name	Active substance	MAH Name	Product Status	Publication Date	Procedur Type	e 🛓	
	Voydeya	Danicopan	Alexion Europe	Authorised	26/06/2024	Initial Marketing Authorisa		•
Showi	ing 1 to 1 of 1 e	entries				Previous	1	Next

Product name Voydeya MAH **Alexion Europe** Active substance Danicopan ATC code L04AJ09 Number of Documents 160 Procedure type Initial Marketing Authorisation Publication year 2024 **Product Status** Authorised Туре 0 Article 58 No EMA procedure number EMEA/H/C/005517/0000



EUROPEAN MEDICAL WRITERS ASSOCIATION

Challenges




- 25 clinical studies
- 160 documents in scope
- Anonymisation for PPD only; no CCI
- Crossfunctional endeavour



- Indicated for paroxysmal nocturnal hemoglobinuria, a rare disease
- Small number of patients in many sites and countries
- Finding the balance between personal data protection and data utility



Voydeya Timeline for EMA Policy 0070



FFFRENC


MEDICAL WEICHAN

Redaction Package Preparation

- Identify documents that are in scope
- Risk assessment and methodology decision
- Anonymisation
- Prepare anonymisation report


- Mod 2.5
- Mod 2.7.1, 2.7.2, 2.7.3, 2.7.4
- Mod 5.0
 - All CSRs and selected Appendices Section 14 Tables & Figures Section 14.3.3 Narratives Section 16.1.1 Protocol +Amendments Section 16.1.2 Sample CRF Section 16.1.9 SAP
 - Mod 5.3.5.3 ISS Outputs








EMMA_ EUROPEAN MEDICAL WRITERS ASSOCIATION





EMA EUROPEAN MEDICAL WRITERS ASSOCIATION

Common anonymisation techniques



- Redaction (blackening out)
- Generalisation/banding
- Recoding/transformation/offsetting

Proactive
AnonymisationReactive
AnonymisationProtect as we
writeWrite now,
anonymise later



Voydeya Anonymisation Report

EMA – Health Canada Common Template

- 1. Anonymisation Methodology
- **2. Identification of Data Variables**
 - **2.1 Direct Identifiers**
 - **2.2 Indirect Identifiers**
- 3. Risk Assessment
- 4. Data Utility
- 5. Deviations

Direct IDs: info that permits direct recognition or communication with the corresponding individuals (name, initials, address, phone numbers, patient ID)

Indirect (quasi) IDs: variables representing an individual's background information that can indirectly identify individuals (dates, demographics, medical history, AEs, etc.)



1. Anonymisation Methodology A) Are there any indirect identifiers present within the clinical information package? (a) Yes (b) No 1. Anonymisation Methodology (c) Yes (c)	 25 clinical studies Sample size range: 8 to 8 Both quantitative and qualitative risk assessments Preserve data utility 		
[If Both] Please list the studies within the submission distinguishing between the qualitative and quantitatively anonymised studies (or documents.) ACH471-001 - Quantitative - PoSA=0.067 ACH471-002 - Quantitative - PoSA=0.091 ACH471-006 - Quantitative - PoSA=0.083 ACH471-009 - Quantitative - PoSA=0.063 ACH471-010 - Quantitative - PoSA=0.063 ACH471-011 - Quantitative - PoSA=0.077 ACH471-012 - Quantitative - PoSA=0.063 ACH471-013 - Quantitative - PoSA=0.091 ACH471-014 - Quantitative - PoSA=0.091 ACH471-017 - Quantitative - PoSA=0.091 ACH471-017 - Quantitative - PoSA=0.091 ACH471-017 - Quantitative - PoSA=0.091 ACH471-012 - Quantitative - PoSA=0.091 ACH471-017 - Quantitative - PoSA=0.091 ACH471-017 - Quantitative - PoSA=0.091 ACH471-017 - Quantitative - PoSA=0.093 ALXN2040-HV-102 - Quantitative - PoSA=0.053 ALXN2040-HV-119 - Quantitative - PoSA=0.091	Quantitative Phase 3 study N=84 PoSA = 0.077		
ALXN2040-PNH-301 - Qualitative - PoSA=0.077 ACH471-100 - Qualitative ACH471-101 - Qualitative ACH471-102 - Qualitative ACH471-102 - Qualitative ACH471-201 - Qualitative ACH471-201 - Qualitative ACH471-205 - Qualitative ACH471-205 - Qualitative - PoSA=0.077 ACH471-205 - Qualitative - PoSA=0.091 ALXN2040-20-0013 - Qualitative PMX-0025 - Qualitative PMX-0038 - Qualitative Clinical-overview - Qualitative		ualitative ase 2 stud N=10	



EMMA EUROPEAN MEDICAL WRITERS ASSOCIATION

2. Identification of Data Variables

5

2.1 Direct Identifiers

D) In the table below, please list the direct identifiers present in the clinical information package. <u>Only include</u> identifiers that are <u>present</u> in the document package.

-			est and the second s			
	Category	Participant/ Personnel	Anonymisation	Comments		
+	Participant/Subject ID	Participant	Yes (Recoded)	No. No.		
+	Participant/Subject ID	Participant	Yes (Redacted)	Exception: redacted in documents containing pooled study data (Module 2, ISE, ISS, PMX-0025, PMX-0038)		
+	Handwritten Text	Personnel	Yes (Redacted)			
+	Name/Initials/Signature	Personnel	No (Retained)	Specific to the corporate office (i.e., not related to an individual)		
+	Name/Initials/Signature	Personnel	Yes (Redacted)	Specific to an individual		
+	Contact Details (Email, Phone & Fax)	Personnel	Yes (Redacted)	Specific to an individual		
+	Contact Details (Email, Phone & Fax)	Personnel	Yes (Redacted)	Exceptions: Sponsor Signatory and Principal Investigator have been retained in the Clinical Study Reports only.		
+	Other Direct Identifier	Personnel	Yes (Redacted)	DocuSign Envelope Identification number, IP address		

- Retained
 - Names of PI and Sponsor in CSRs
 - Corporate addresses & contact details

Recoded/Transformed

• Patient ID

Redacted

- Names, signature (wet ink, eSig, IP address)
- Contact details of an individual



2. Identification of Data Variables

2.2 Indirect Identifiers

Category¤	Participant/' Personnel¤	¶ Anonymisation¤	Comments¤
Demographics - Sex/Gender¤	Participant¤	Yes (Redacted)¤	¤
Demographics - Sex/Gender¤	¤ Participant¤	¤ No (Retained)¤	ACH471-002, ACH471-005, ACH471-006,¤ ACH471-010, ACH471-012, ACH471-017, ALXN2040-PNH-301¤
Demographics - Ethnicity¤	Participant¤	Yes (Redacted)¤	¤
Demographics - Ethnicity¤	Participant¤	No (Retained)¤	ACH471-101¤
Demographics - Age¤	Participant¤	Yes (Generalized)¤	Age group bands were utilized¤
Demographics - Age¤	Participant¤	Yes (Redacted)¤	ALXN2040-HV-101, ACH471-005, ACH471- 100, ACH471-103, ACH471-201,¶ Module 2 documents, ISE, ISS, PMX-0025, · PMX-0038¤
Demographics - Race¤	Participant¤	Yes (Redacted)¤	a
Demographics - Race¤	Participant¤		ACH471-001: White was kept, all other low · frequency races were redacted¤
Demographics - Race¤	Participant¤	No (Retained)¤	ALXN2040-HV-101, ALXN2040-HV-119¤
Demographics - BMI¤	Participant¤	Yes (Redacted)¤	¤
Demographics - Height¤	Participant¤	Yes (Redacted)¤	a
Demographics - Body Weight¤	Participant¤	Yes (Redacted)¤	α

Sex/Gender

- Redacted by default
- Retained in Phase 1 study (all males), study with n > 80

Age

- Generalised (age groups)
- Redacted in studies with outliers

Race/Ethnicity

- Redacted
- Retained in single race study
- Kept "White", redacted minority groups or recoded as "other"

Singling out or uniqueness



M EUROPEAN MEDICAL WRITERS ASSOCIATION

2. Identification of Data Variables

2.2 Indirect Identifiers

		· -		
	Category	Participant/ Personnel	Anonymisation	Comments
+	Adverse Event Terms	Participants	No (Retained)	
+	Adverse Event Terms	Participants	Yes (Redacted)	Exceptions: terms within a rare disease population that are identified as visibly identifiable, rare, newsworthy, or has a negative association.

Records - Medical History	Participant	No (Retained)	
Records - Medical History	Participant	Yes (Redacted)	Exceptions: terms identified as visibly identifiable, rare, newsworthy, have a negative association, or disclose the sex of the participant in a study where sex is redacted.
Records - Concomitant Medications	Participant	No (Retained)	
Records - Concomitant Medications	Participant	Yes (Redacted)	Exceptions: when medications are linked with rare and/or sensitive information, or have a negative association, which could result in harm to the participant in the case of successful re-identification. Also redacted when it would disclose the sex of the participant in a study where sex is redacted.

J.	Demographics - Douy rreight	ганисранс	res (iveuacteu)	L
	Date/Day - Relative Day	Participant	No (Retained)	
	Date/Day - Calendar Date	Participant	Yes (Offset)	Specific to a participant.
I	Date/Day - Calendar Date	Participant	Yes (Redacted)	Exception: redacted in documents containing pooled study data (Module 2 documents, ISE, ISS, PMX-0025, PMX-0038)

Adverse events / medical history

- Retained
- Redacted if "sensitive"

Concomitant medications

- Retained
- Redacted if "sensitive"
- Redacted if info is inferential
 - Conmeds that "give away" sex, geographic location


Inference

Dates

- Retained if relative day (eg, Study Day 1)
- Redacted / Transformed if calendar date



2. Identification of Data Variables (Examples not from Voydeya)



Sweeney, 1979 on linkage

Last voting date

Party affiliation



3. Risk Assessment

	15°
3. Risk Assessment	
F) Please input the selected reference populati	on.
Study participants enrolled in each individual CTs	in this submission
G) Is this product indicated in the treatment of	a rare disease/condition?
Yes	200
O No	Nº NO
H) Were special populations involved in the tri	als?
Yes	all
O No	N AN
Please describe the characteristics of the speci	al population(s) below.
An older population was included; for instance, in	the phase 3 shoty AQN2040-PNH-301, over 25% of patients were aged 65-84.
I) Please input initial risk of reidentification.	1 and tailing a
J) Please input target risk threshold.	0.091 and Low
K) Please input residual risk.	Section 1.B states the quantitative results; Low for qualitative studies
L) Did some of the above indirect identifiers re	guire consideration due to the sensitivity of the information?
Yes	
ON₀ (⁵) [×]	
Please list the categories of identifiers which w	ere deemed sensitive by the applicant.
adverse event terms, medical distory terms, and o in population at large, or a disease diagnosis identification was high as these identifiers were v in harm to the participant in the case of successfu	qualitative approach and related to study participants were redacted. These included: concomitant medication. This sensitive information (e.g., adverse event that was unique) was qualitatively assessed by experts and redacted only when the risk of re- isibly identifiable, rare, newsworthy, or have a negative association, which could result I re-identification. Redactions were also implemented for terms that indicated the sex study. Lastly, redactions were implemented for sensitive terms, which occurred

Where a contract medication was linked with such a rare and/or sensitive information, or indicated the sex of the participant when sex was redacted in that study, the concomitant medication was also redacted. This also occurred infrequently.

Sensitive information (redacted)

AEs, medical history terms, and concomitant medication which are

- unique in the population
- rare disease diagnosis (other than the indication)
- newsworthy
- have a negative association





ENVAL EUROPEAN MEDICAL WRITERS ASSOCIATION

infrequently.

4. Data Utility

4. Data Utility

N) List the variables with the highest data utility (up to five). Gender, age, adverse events, medical history

O) How was data utility loss mitigated for these variables?

Alexion utilized a validated software to measure risk and anonymize the clinical documents for this submission. The software calculates a re-identification risk value for each participant enrolled in the clinical trial based on K-anonymity. Alexion thoroughly considered the balance of data utility and privacy when applying the anonymization method to this submission. Data utility was maximized by including a quantitative risk assessment, appropriate reference population selection, and the anonymization of personal data using randomization and offsetting. When the risk assessment did not allow the application of specific anonymization methods due to the limitation of the sample size of the study, redaction was applied to protect participant privacy. Summary information included in this submission was retained.

Therefore, where possible (i.e., in quantitatively-assessed studies), age was banded and gender was retained. Adverse events were a priority for retention as was medical history; both were qualitatively assessed by experts and retained except in unique instances where the term was assessed to be a high-risk identifier (i.e., visibly identifiable, rare, newsworthy, or has a negative association), or the term indicated the sex of the participant when sex was redacted in that study. All adverse events were retained on the summary level.

P) Have aggregate tables been appropriately retained?	200 Inc	
• Yes	en la	
⊖ No		

Gender Age AEs Medical history


Data with highest utility Retained or banded



Exceptions are sensitive data and outliers REDACTED



EWA EUROPEAN MEDICAL WRITERS ASSOCIATION



Anonymisation (Dummy data, not from Voydeya)

Before

After

	ID#	Initiais	Location	Age (Y)	Gender	Race	HISTORY
	001	JP	Zurich	30	Female	White	Cancer
	002	AM	London	24	Female	White	Viral infection
	003	RB	Copenhagen	28	Female	Black	ТВ
	004	JM	Manchester	27	Male	Asian	Cardiovascula r
	005	TR	Amsterdam	24	Female	Native Am	Heart-related
	006	SB	Geneva	23	Male	White	ТВ
	007	ST	Berlin	19	Male	White	Cancer
	008	RC	Zurich	29	Male	White	Cardiovascula r
Reco	ding	Redaction	Generalisation	Banding	Retain	Generalisation	Retain ula
	010 D #	bitials		Age (Y)	MGender	OtherRace	Viral iHistaby
	000	PPD PPD		Age (Y) 20 < Age ≤ 30	M Gender Female	Other Race	Viral Hista 55 Cancer
	010 D #		ondencation			Other Race	
	010 D# 185	PPD	Onconcation Switzerland	20 < Age ≤ 30	Female	Other Race White	Cancer
	010 D# 185 281	PPD PPD	Onconcation Switzerland UK	20 < Age ≤ 30 20 < Age ≤ 30	Female Female	Other Race White White	Cancer Viral infection
	010 D# 185 281 383	PPD PPD PPD	Onconcation Switzerland UK Denmark	20 < Age ≤ 30 20 < Age ≤ 30 20 < Age ≤ 30 20 < Age ≤ 30	Female Female Female	Other Race White White Other	Cancer Viral infection TB
	010 D# 185 281 383 427	PPD PPD PPD PPD	Onconcation Switzerland UK Denmark UK	$20 < Age \le 30$ $20 < Age \le 30$ $20 < Age \le 30$ $20 < Age \le 30$ $20 < Age \le 30$	Female Female Female Male	Other White White Other Other	Cancer Viral infection TB Cardiovascular
	010 D# 185 281 383 427 587	PPD PPD PPD PPD PPD PPD	Ondercation Switzerland UK Denmark UK Netherlands	$20 < Age \le 30$ $20 < Age \le 30$	Female Female Female Male Female	Other White White Other Other Other	Cancer Viral infection TB Cardiovascular Heart-related
	010 D# 185 281 383 427 587 651	PPD PPD PPD PPD PPD PPD	Ondercation Switzerland UK Denmark UK Netherlands Switzerland	$20 < Age \le 30$ $20 < Age \le 30$	Female Female Female Male Female Male	Other White White Other Other Other White	Cancer Viral infection TB Cardiovascular Heart-related TB
	010 ^{D#} 185 281 383 427 587 651 725	PPD PPD PPD PPD PPD PPD PPD PPD	Ondercation Switzerland UK Denmark UK Netherlands Switzerland Germany	$20 < Age \le 30$ $20 < Age \le 30$ $Age \le 20$	Female Female Female Male Female Male Male	Other White White Other Other Other White White	Cancer Viral infection TB Cardiovascular Heart-related TB Cancer
AEDICAL WRI	010 D# 185 281 383 427 587 651 725 155 823 250	PPD PPD	Ondercation Switzerland UK Denmark UK Netherlands Switzerland Germany Switzerland	$20 < Age \le 30$ $20 < Age \le 30$ $Age \le 20$ $20 < Age \le 30$	Female Female Male Female Male Male Male Male	Other White Other Other Other White White White	Cancer Viral infection TB Cardiovascular Heart-related TB Cancer Cardiovascular



WA_ EUROPEAN MEDICAL WRITERS ASSOCIATION

Medical Writing Learnings


Phase 3 CSR was written with disclosure & data protection in mind (proactive anonymisation)

- No CCI
- No patient ID, demographics were used in the CSR body.
- Direct and indirect IDs only used in Section 14.3.3 Narratives
- CSR body required very minimal redaction.

Additional reactive anonymisation

- Patient IDs were recoded.
- Age was banded.
- Redaction was limited to information that are unique, sensitive, inferential.

Similar approach in Clinical Modules



A big thank you to the cross-functional team who developed the Voydeya disclosure package

- CT Transparency
- Medical Writing
- Regulatory Affairs
- Biostatistics
- Legal Counsel

